Patients classification by Hoehn and Yahr staging and Non-Motor Symptoms burden levels.

<p>Goodman and Kruskal's gamma = 0.45; ASE = 0.032.</p

Non-Motor Symptoms Scale domains scores broken down by burden levels.

*<p>Kruskal-Wallis test for all variables, p =  0.0001.</p><p>Bonferroni correction for multiple (n = 22) comparisons, p<0.0023.</p><p>NMS: Non-Motor Symptoms. NMSS: Non-Motor Symptoms Scale.</p

Variables in the study broken down by the NMS burden levels and Hoehn and Yahr staging^*.

<p>PD: Parkinson's disease. NMS: Non-Motor Symptoms. NMSS: Non-Motor Symptoms Scale. SCOPA: Scales for Outcomes in Parkinson's Disease. CISI-PD: Clinical Impression of Severity Index for Parkinson's disease. VAS: Visual analogue scale. PDQ-8: Parkinson's Disease Questionnaire-8 items.</p>*<p>Kruskal-Wallis test for all variables, p =  0.0001. Bonferroni correction for multiple (n = 18) comparisons, p<0.0027.</p

Main characteristics of the sample.

<p>SD: Standard deviation. SCOPA: Scales for Outcomes in Parkinson's Disease. PDQ-8: Parkinson's Disease Questionnaire-8 items.</p

Results of univariate and multivariate analyses to examine clinical parameters associated with executive function performance, composite speed and basal ganglia mI/Cr ratio.

<p>Results of univariate and multivariate analyses to examine clinical parameters associated with executive function performance, composite speed and basal ganglia mI/Cr ratio.</p

Results of cerebral function assessments and univariate regression analysis to investigate differences between subject groups.

<p>[Legend <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038980#pone-0038980-t002" target="_blank">Table 2:</a><i>FGM =  frontal grey matter; FWM = frontal white matter; BG = basal ganglia; NAA = N-acetyl aspartate; Cr = creatine; Cho = choline; mi = myo-inositol peak</i>].</p

Patient demographics, clinical parameters and study participation of subjects completing neurocognitive testing (NCT) procedures.

<p><a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0038980#pone-0038980-t001" target="_blank">Table 1</a> legend: HCV = hepatitis C virus; RNA: ribonucleic acid; ALT  =  alanine aminotransferase; IU = international units;</p>†<p>1 subject had VL 87 copies/mL at time of assessment, repeat <50 copies/mL, *using Fisher’s exact test or t-test].</p

Box-plots to demonstrate PK11195 Binding Potential (BP) in parietal and frontal locations according to Combination Antiretroviral therapy (cART) status.

<p>Box-plots to demonstrate PK11195 Binding Potential (BP) in parietal and frontal locations according to Combination Antiretroviral therapy (cART) status.</p

Results of univariate and multivariate analyses to examine clinical parameters associated with occipital, parietal and frontal PK11195 Binding Potential (BP).

<p>Results of univariate and multivariate analyses to examine clinical parameters associated with occipital, parietal and frontal PK11195 Binding Potential (BP).</p